lotrafiban has been researched along with piperidines in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (81.25) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amarenco, P; Califf, R; Chan, R; Davis, S; Diener, HC; Easton, JD; Ferguson, J; Fitzgerald, D; Graffagnino, C; Granett, J; Harrington, R; Ilson, B; Koudstaal, PJ; Samuels, R; Shuaib, A; Theroux, P; Topol, EJ; Van de Werf, F; Willerson, JT | 1 |
| Armstrong, PW; Califf, RM; Card, T; Chan, R; Graffagnino, C; Granett, J; Harrington, RA; Joseph, DM; Kereiakes, DJ; Samuels, R; Sigmon, KN; Topol, EJ; Van De Werf, F | 1 |
| Carroll, RC; Craft, RM; Liu, F; Morris, SA | 1 |
| SoRelle, R | 1 |
| Aluri, J; Chapelsky, M; Granett, J; Mould, D; Samuels, R; Swagzdis, J | 1 |
| Barone, FC; Erhardt, JA; Gabriel, MA; Ohlstein, EH; Parsons, AA; Toomey, JR; Willette, RN; Yue, TL | 1 |
| Ma, D; Xia, C | 1 |
| Billheimer, JT; He, B; Seiffert, D; Spitz, SM; Stern, AM | 1 |
| Barone, FC; Koster, PF; Samanen, J; Toomey, JR; Valocik, RE; Willette, RN | 1 |
| Amarenco, P; Califf, RM; Davis, S; Diener, HC; Easton, D; Ferguson, J; Fitzgerald, D; Graffagnino, C; Granett, J; Harrington, RA; Koudstaal, PJ; Pieper, K; Shuaib, A; Sigmon, K; Theroux, P; Topol, EJ; Vallee, M; Van de Werf, F; Willerson, JT | 1 |
| Salam, AM | 1 |
| Best, D; Jarvis, GE; Watson, SP | 1 |
| Berndt, MC; Calaminus, SD; Machesky, LM; McCarty, OJ; Watson, SP | 1 |
| Aitken, EW; Harper, MT; Jones, ML; Poole, AW; Williams, CM | 1 |
| Buckley, CD; Dhanjal, TS; Mazharian, A; Thomas, SG; Watson, SP | 1 |
| Feuerstein, G; Gerstenhaber, JA; Lelkes, PI; Marcinkiewicz, C; Sternberg, M | 1 |
1 review(s) available for lotrafiban and piperidines
| Article | Year |
|---|---|
Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.
Topics: Animals; Benzodiazepines; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex | 2000 |
4 trial(s) available for lotrafiban and piperidines
| Article | Year |
|---|---|
Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial.
Topics: Administration, Oral; Adolescent; Arterial Occlusive Diseases; Benzodiazepines; Double-Blind Method; Drug Evaluation; Female; Humans; Ischemic Attack, Transient; Male; Myocardial Infarction; Myocardial Ischemia; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Research Design; Secondary Prevention; Stroke | 2000 |
Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease.
Topics: Administration, Oral; Aged; Benzodiazepines; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemorrhage; Humans; Intracranial Arteriosclerosis; Male; Middle Aged; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Treatment Outcome | 2000 |
A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients.
Topics: Adult; Age Factors; Aged; Benzodiazepines; Creatinine; Demography; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Diseases; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sex Factors | 2001 |
Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Benzodiazepines; Cerebrovascular Disorders; Coronary Disease; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Risk Assessment; Treatment Outcome | 2003 |
11 other study(ies) available for lotrafiban and piperidines
| Article | Year |
|---|---|
SmithKline Beecham halts tests of lotrafiban, an oral glycoprotein IIb/IIIa inhibitor.
Topics: Administration, Oral; Benzodiazepines; Clinical Trials, Phase III as Topic; Hemorrhage; Humans; Myocardial Infarction; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stroke; Treatment Outcome | 2001 |
Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban.
Topics: Animals; Benzodiazepines; Caspase 3; Caspases; Cells, Cultured; Coumarins; Enzyme Activation; Fibrinolytic Agents; Heart; Myocardium; Oligopeptides; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Rats; Rats, Sprague-Dawley | 2001 |
CuI-catalyzed coupling reaction of beta-amino acids or esters with aryl halides at temperature lower than that employed in the normal Ullmann reaction. Facile synthesis of SB-214857.
Topics: Amino Acids; Benzodiazepines; Catalysis; Copper; Hydrocarbons, Halogenated; Piperidines; Platelet Glycoprotein GPIIb-IIIa Complex; Stereoisomerism | 2001 |
Effects of glycoprotein IIb/IIIa antagonists on platelet activation: development of a transfer method to mimic peak to trough receptor occupancy.
Topics: Alanine; Amidines; Benzodiazepines; Blood Platelets; Humans; In Vitro Techniques; Isoxazoles; Oximes; P-Selectin; Piperidines; Platelet Adhesiveness; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Thrombosis | 2002 |
The antithrombotic efficacy of lotrafiban (SB 214857) in canine models of acute coronary thrombosis.
Topics: Acute Disease; Animals; Benzodiazepines; Coronary Thrombosis; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Male; Piperidines; Platelet Aggregation | 2002 |
Is there a role for oral blockade of platelet glycoprotein IIb/IIIa receptors in coronary and cerebrovascular disease?
Topics: Administration, Oral; Benzodiazepines; Coronary Disease; Humans; Piperidines; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Stroke | 2003 |
Differential roles of integrins alpha2beta1 and alphaIIbbeta3 in collagen and CRP-induced platelet activation.
Topics: Adenosine Diphosphate; Benzodiazepines; Carrier Proteins; Collagen; Cytoplasmic Granules; Dual Specificity Phosphatase 2; Humans; Integrin alpha2beta1; P-Selectin; Peptides; Piperidines; Platelet Activation; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Protein Phosphatase 2; Protein Tyrosine Phosphatases; Thromboxane A2 | 2004 |
von Willebrand factor mediates platelet spreading through glycoprotein Ib and alpha(IIb)beta3 in the presence of botrocetin and ristocetin, respectively.
Topics: Actin Cytoskeleton; Animals; Benzodiazepines; Blood Platelets; Crotalid Venoms; Cytoskeleton; Humans; In Vitro Techniques; Mice; Mice, Knockout; Neuropeptides; Phosphatidylinositol 3-Kinases; Piperidines; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Platelet Glycoprotein GPIIb-IIIa Complex; Pseudopodia; rac GTP-Binding Proteins; rac1 GTP-Binding Protein; RAC2 GTP-Binding Protein; Ristocetin; Signal Transduction; src-Family Kinases; von Willebrand Factor | 2006 |
RGD-ligand mimetic antagonists of integrin alphaIIbbeta3 paradoxically enhance GPVI-induced human platelet activation.
Topics: Benzodiazepines; Biomimetics; Blood Coagulation; Blood Platelets; Calcium Signaling; Enzyme Activation; Humans; Immunoglobulin gamma-Chains; Intracellular Signaling Peptides and Proteins; Ligands; Oligopeptides; Phosphatidylserines; Phosphorylation; Piperidines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Protein Conformation; Protein-Tyrosine Kinases; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Secretory Vesicles; src-Family Kinases; Syk Kinase; Time Factors; Tirofiban; Tyrosine | 2010 |
Critical role of Src-Syk-PLC{gamma}2 signaling in megakaryocyte migration and thrombopoiesis.
Topics: Animals; Benzodiazepines; Blood Platelets; Cell Movement; Cell Shape; Cells, Cultured; Intracellular Signaling Peptides and Proteins; Megakaryocytes; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxazines; Phospholipase C gamma; Phosphorylation; Piperidines; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Proto-Oncogene Proteins pp60(c-src); Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Pyridines; Pyrimidines; Signal Transduction; Syk Kinase; Thrombopoiesis | 2010 |
Bitistatin-functionalized fluorescent nanodiamond particles specifically bind to purified human platelet integrin receptor α
Topics: Animals; Benzodiazepines; Blood Platelets; Fibrinogen; Humans; Nanodiamonds; Peptides; Piperidines; Platelet Activation; Platelet Glycoprotein GPIIb-IIIa Complex; Rats, Inbred F344; Receptors, Fibrinogen; Snake Venoms; Thrombin; Thrombosis | 2017 |